** Shares of drug developer CERo Therapeutics CERO.O rise 11% to $7.65 premarket
** Co says its experimental blood cancer therapy, CER-1236, received U.S. FDA's "fast track" tag
** FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need
** The therapy is being tested in an early stage trial for patients with aggressive forms of acute myeloid leukemia, a type of blood and bone marrow cancer
** Stock down 94% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))